Results from the BEATcc open-label randomized phase 3 trial: atezolizumab with bevacizumab plus chemotherapy for the treatment of metastatic, persistent, or recurrent cervical cancer
In this medfyle
In this phase 3 study, the addition of atezolizumab to standard of care bevacizumab and chemotherapy showed significant and clinically meaningful improvements in PFS and OS for the treatment of metastatic, persistent, or recurrent cervical cancer.
About this Medfyle
©2024 Medfyle. All rights reserved.
Original article:
Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C, Pérez-Fidalgo JA, Yunokawa M, Dahlstrand H, D'Hondt V, Randall LM; ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 Investigators. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet. 2024 Jan 6;403(10421):31-43. doi: 10.1016/S0140-6736(23)02405-4. Epub 2023 Dec 1. PMID: 38048793.
The summary content was prepared by Rhian Shurlock for Medfyle, and reviewed by Marianna Aita, MD.
The authors of the original article and the publisher were not involved in the creation of the summary.
